Creso Pharma Revenue and Competitors
Estimated Revenue & Valuation
- Creso Pharma's estimated annual revenue is currently $2.6M per year.
- Creso Pharma's estimated revenue per employee is $155,000
Employee Data
- Creso Pharma has 17 Employees.
- Creso Pharma grew their employee count by -26% last year.
Creso Pharma's People
| Name | Title | Email/Phone |
|---|
Creso Pharma Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Creso Pharma?
Creso was created to bring pharmaceutical expertise and methodological rigour to the world of cannabis and deliver quality products to people and animals everywhere. Founded by a team of highly-experienced pharmaceutical executives, Creso set out to leverage cutting edge science and research to develop, register and commercialise innovative cannabis and hemp derived products.
keywords:N/A
N/A
Total Funding
17
Number of Employees
$2.6M
Revenue (est)
-26%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Creso Pharma News
Creso Pharma secures LOI for commercialisation with Laboratorios Brouwer to broaden LATAM market sales. We are confident that this LOI will...
Creso Pharma plans to bring the best of cannabis to better the lives of people and animals through its pharmaceutical expertise. The company...
Creso Pharma hits major mushroom milestones. Halucenex has completed a series of renovations to its grow rooms at its medical facility in Nova...
Other Companies in Barangaroo
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $3M | 21 | -5% | N/A |
#2 | $2.7M | 23 | N/A | N/A |
#3 | $4.6M | 35 | 30% | N/A |
#4 | $7M | 54 | 32% | N/A |
#5 | $13.7M | 60 | 5% | N/A |